Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Bearish
3
Neutral
7
Bullish
4
Bearish
12
Neutral
7
Bullish
27
Bearish
9
Neutral
0
Bullish
23
Zydus Lifesciences Limited is a leading pharmaceutical company in India involved in the innovation, manufacturing, marketing, and selling of human formulations, APIs, animal healthcare products, and consumer wellness products.
The company reported a robust 17% YoY growth in total revenues in Q2 FY26, driven by strong performances across its business segments, including US formulations and India branded formulations.
Zydus has successfully expanded internationally by acquiring Comfort Click Ltd, strengthening its position in the consumer wellness sector within the UK, EU, and US markets.
Zydus Lifesciences achieved a notable EBITDA margin of 32.9% in Q2 FY26, reflecting a 500 basis points increase YoY, underpinned by sustained operating profitability across its core segments.
Significant progress in innovation includes Zydus' first trivalent influenza vaccine, VaxiFlu, and advancing NCE development with Saroglitazar Magnesium, showing positive results in pivotal clinical trials for Primary Biliary Cholangitis.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs & Formln Lrg
91,049 Cr
Low Risk
17.8
26.2
—
3.6
1,059.00
797.05
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1331.70 | 1,07,503 Cr | 22.62 | 3.27 | 1.20 | 16.53 | 21.05 | 11.32 | |
1268.60 | 1,05,798 Cr | 19.01 | 2.94 | 0.63 | 16.03 | 18.66 | 10.16 | |
2199.20 | 1,00,496 Cr | 20.20 | 5.12 | 0.55 | 22.03 | 21.92 | 13.94 | |
904.80 | 91,049 Cr | 17.80 | 3.60 | 1.22 | 19.44 | 19.08 | 10.52 | |
2060.60 | 85,050 Cr | 45.78 | 5.56 | 0.00 | 11.45 | 12.34 | 6.26 | |
1155.45 | 66,705 Cr | 19.00 | 1.90 | 0.00 | 9.77 | 12.69 | 6.63 | |
5400.00 | 64,584 Cr | 27.47 | 4.84 | 0.83 | 17.69 | 18.13 | 11.95 |
Zydus Lifesciences Ltd (ZYDUSLIFE) is currently trading at 904.80 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Zydus Lifesciences Limited is a leading pharmaceutical company in India involved in the innovation, manufacturing, marketing, and selling of human formulations, APIs, animal healthcare products, and consumer wellness products. The company reported a robust 17% YoY growth in total revenues in Q2 FY26, driven by strong performances across its business segments, including US formulations and India branded formulations. Zydus has successfully expanded internationally by acquiring Comfort Click Ltd, strengthening its position in the consumer wellness sector within the UK, EU, and US markets. Zydus Lifesciences achieved a notable EBITDA margin of 32.9% in Q2 FY26, reflecting a 500 basis points increase YoY, underpinned by sustained operating profitability across its core segments. Significant progress in innovation includes Zydus' first trivalent influenza vaccine, VaxiFlu, and advancing NCE development with Saroglitazar Magnesium, showing positive results in pivotal clinical trials for Primary Biliary Cholangitis.
Over the past 52 weeks, Zydus Lifesciences Ltd has traded between a low of ₹797.05 and a high of ₹1,059.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Zydus Lifesciences Ltd has a market capitalization of approximately 91,049.08. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Zydus Lifesciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 17.80 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 91,049.08 Cr, Zydus Lifesciences Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Zydus Lifesciences Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Zydus Lifesciences Ltd is 17.80. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Zydus Lifesciences reported a 30.3% year-on-year revenue growth to ₹6,864.5 crore and a 9% increase in adjusted net profit to ₹1,110 crore, driven by strong performance in its North America and India businesses.
Zydus Lifesciences reported a 30.3% year-on-year increase in revenue to Rs 6,864.5 crore and a 30.9% rise in EBITDA to Rs 1,816.4 crore. Net profit grew by nearly 2% to Rs 1,042 crore.
The 'Biopharma Shakti' scheme, with a ₹10,000 crore outlay, is the most significant announcement. It directly supports Zydus's strategic focus on developing and manufacturing biologics and biosimilars, aiming to make India a global hub.
Zydus Lifesciences is in talks to acquire US biopharma firm Ardelyx, potentially by purchasing a controlling stake or its key molecules. Ardelyx is valued at approximately $1.6 billion.
Regulatory Approval
Zydus Lifesciences received final USFDA approval for Ammonium Lactate Cream 12%, to be manufactured at Changodar and distributed by Viona; the product had ~USD15M annual US sales (IQVIA MAT Dec 2025).
Litigation Settlement
Zydus Lifesciences and its US subsidiary entered a settlement with Astellas resolving US Mirabegron patent litigation; Zydus will pay USD 120 million plus a prepaid per‑unit licensing fee through Sept 2027 and may continue marketing its generic in the US.
Investor Meeting Outcome
The company has made available an audio recording of its Investor Call discussing its financial results for the quarter/nine months ended December 31, 2025.
Financial Results
Zydus Lifesciences Limited published its unaudited financial results for the quarter and nine months ended December 31, 2025, in the Financial Express on February 10, 2026.
Financial Results
Zydus Lifesciences Limited announces its unaudited financial results for Q3 and nine months ended December 31, 2025, showing significant growth in revenue and profit.
Investor Presentation
Zydus Lifesciences announced their investor presentation detailing the unaudited financial results for the quarter and nine months ended December 31, 2025.
